(function(){var loadHandler=window['sl_{DC1F7540-1882-43D0-A075-6AAB30A2CE8C}'];loadHandler&&loadHandler(6, '<div id="spr0_5dc05b7d"><div id="spr1_5dc05b7d" class="kern slide"><img id="img4_5dc05b7d" src="data/img1.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_5dc05b7d" class="kern slide"><img id="img0_5dc05b7d" src="data/img10.png" width="721.48" height="112.997" alt="" style="left:-1.48px;top:-0px;"/><div id="svg1_5dc05b7d" style="left:-1.48px;top:0.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#2e3546" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><img id="img1_5dc05b7d" src="data/img3.png" width="721.48" height="43.101" alt="" style="top:496.899px;"/><div id="spr3_5dc05b7d" style="left:657.715px;top:499.855px;"><img id="img2_5dc05b7d" src="data/img4.png" width="56" height="36" alt="CHRC logo_with text.psd" style="left:-0.105px;top:-0.177px;"/></div><div id="spr4_5dc05b7d" style="left:-1.633px;"><div style="width:0px;"><span id="txt0_5dc05b7d" data-width="285.765625" style="left:217.35px;top:5.086px;">ODYSSEY OUTCOMES</span></div><div style="width:0px;"><span id="txt1_5dc05b7d" data-width="634.101563" style="left:44.085px;top:43.301px;">Relative and Absolute Risk Reduction with Alirocumab By</span></div><div style="width:0px;"><span id="txt2_5dc05b7d" class="relpos" data-width="172.265625" style="left:236.685px;top:76.901px;">Glucometabolic</span><span id="txt3_5dc05b7d" class="relpos" style="left:236.68px;top:84.362px;">Â </span><span id="txt4_5dc05b7d" class="relpos" data-width="70.164063" style="left:236.675px;top:76.901px;">Status</span></div></div><div id="spr5_5dc05b7d" style="left:13.757px;top:504.073px;"><div style="width:0px;"><span id="txt5_5dc05b7d" class="nokern" data-width="172.331543" style="left:7.2px;top:9.471px;">Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628.</span></div></div><div id="spr6_5dc05b7d" style="left:13.757px;top:464.091px;"><div style="width:0px;"><span id="txt6_5dc05b7d" class="nokern" data-width="194.020020" style="left:7.2px;top:4.111px;">Median (Q1, Q3) follow-up: 2.8 (2.3, 3.4) years</span></div></div><div id="spr7_5dc05b7d" style="top:120.171px;"><img id="img3_5dc05b7d" src="data/img11.png" width="720" height="344" alt="A screenshot of a cell phone  Description automatically generated" style="top:-0.04px;"/></div><div id="svg3_5dc05b7d" style="left:-1.48px;top:111.154px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#c76c02" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div></div></div>');})();